Anika Therapeutics (ANIK) Receivables (2016 - 2025)
Historic Receivables for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $23.1 million.
- Anika Therapeutics' Receivables fell 2544.7% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year decrease of 2544.7%. This contributed to the annual value of $24.3 million for FY2024, which is 999.78% down from last year.
- Per Anika Therapeutics' latest filing, its Receivables stood at $23.1 million for Q3 2025, which was down 2544.7% from $24.8 million recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Receivables registered a high of $38.4 million during Q2 2023, and its lowest value of $22.7 million during Q1 2025.
- Its 5-year average for Receivables is $30.3 million, with a median of $31.1 million in 2021.
- In the last 5 years, Anika Therapeutics' Receivables skyrocketed by 4060.58% in 2021 and then tumbled by 3270.19% in 2025.
- Anika Therapeutics' Receivables (Quarter) stood at $31.3 million in 2021, then increased by 15.82% to $36.2 million in 2022, then fell by 25.41% to $27.0 million in 2023, then fell by 10.0% to $24.3 million in 2024, then dropped by 5.21% to $23.1 million in 2025.
- Its Receivables stands at $23.1 million for Q3 2025, versus $24.8 million for Q2 2025 and $22.7 million for Q1 2025.